One previous MR study has verified significant association of genetically increased serum IL-6 receptor (IL-6R) levels with reduced risk of MS, and speculated that inhibiting IL-6 signaling (such as tocilizumab treatment) would be an effective therapy for MS (17). This evidence concerns the gene IL6R and myeloid sarcoma.